Bayer’s Copanlisib (Aliqopa) Approved by NMPA for Recurrent Follicular Lymphoma
The National Medical Products Administration (NMPA) has indicated on its website that Bayer’s (ETR: BAYN)...
Drug
3SBio Inc. Initiates Phase III Clinical Study for Thrombopoietin in Chronic Liver Disease Patients
China-based 3SBio Inc. (HKG: 1530) has announced the enrollment of the first patient in a...
Shanghai Junshi Biosciences’ Tuoyi Combo for Triple Negative Breast Cancer Accepted for Review
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced that the regulatory authorities...
Oculis’ OCS-01 Achieves Primary Efficacy Endpoint in Phase III DIAMOND Trial for DME
US-based Oculis Holding AG (NASDAQ: OCS) has announced positive top-line results from Stage 1 of...
SinoMab BioScience’s SM17 IND Accepted by NMPA for Potential Global First-in-Class Monoclonal Antibody
Hong Kong-based biotech SinoMab BioScience Ltd (HKG: 3681) has announced that the National Medical Products...
HighTide Therapeutics’ HTD1801 Meets Primary and Secondary Endpoints in Type 2 Diabetes Phase II Study
China-based HighTide Therapeutics Inc. (HKG: 2511) has announced that its Phase II study for the...
Zhejiang Conba Pharmaceutical’s Inhalable Pirfenidone for IPF Clears for Chinese Clinical Trials
Zhejiang Conba Pharmaceutical Co., Ltd (SHA: 600572) has announced that its modified version of US...
Jiangsu Hengrui Pharmaceuticals Receives NMPA Approval for Two Autoimmune Disease Drug Candidates
China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has separately announced clinical trial approvals from the National...
Sino-US Laekna Receives FDA Clearance for LAE102 Clinical Trial in NSCLC
Sino-US Laekna has announced that it has received clinical trial clearance from the US Food...
Cabaletta Bio’s CABA-201 Clears FDA for Phase I/II Study in Idiopathic Inflammatory Myopathy
US-based Cabaletta Bio, Inc. (NASDAQ: CABA) has announced that the US Food and Drug Administration...
Abbisko Therapeutics and X4 Pharmaceuticals Announce Positive Phase III Results for Mavorixafor in WHIM Syndrome
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) and its US partner X4 Pharmaceuticals Inc....
FibroGen’s Roxadustat Shows Positive Results in Phase III Chemotherapy-Induced Anemia Trial
US-based FibroGen Inc. (NASDAQ: FGEN) has announced positive topline data from a Phase III trial...
NMPA Approves Nanjing Sanhome’s Alfosbuvir for Chronic Hepatitis C Treatment
Nanjing Sanhome Pharmaceutical Co., Ltd has announced that its Category 1 drug alfosbuvir has been...
Betta Pharmaceuticals Initiates Phase I/II Study for First-In-Class BsAb BPB-101
China’s Betta Pharmaceuticals (SHE: 300558) has announced the enrollment of the first patient in a...
Antengene’s First-in-Class CD24 mAb ATG-031 Gets US FDA Approval for Phase I Study
Antengene Corp., Ltd (HKG: 6996) has announced that it has received approval from the US...
BioRay Pharmaceutical’s Zuberitamab Approved by NMPA for CD20 Positive DLBCL Treatment
BioRay Pharmaceutical Co., Ltd has announced that its drug zuberitamab has been approved by the...
WestVac Biopharma Receives FDA Approval for COVID-19 Protein Vaccines Targeting XBB Variants
Chengdu-based WestVac Biopharma Co., Ltd has announced receiving clinical trial approval from the National Medical...
CARSgen Therapeutics Initiates Phase II Study for CT041 in Advanced Gastric Cancer
China-based chimeric antigen receptor (CAR)-T cell specialist CARSgen Therapeutics Holdings Ltd (HKG: 2171) has announced...
CDE Lists Three Home-Grown Drugs for Priority Review, Including Myopia Treatment
The Center for Drug Evaluation (CDE) website has indicated that three home-grown drugs are on...
BeiGene and The Max Foundation Collaborate to Expand Access to Brukinsa for CLL Patients
China-based biotech BeiGene (NASDAQ: BGNE) has formed a collaboration with US-based non-profit organization The Max...